Improved Methods for Catalyst Recovery in Biopharmaceutical Production
Active Pharmaceutical Ingredient (API) processes employ catalytic organic syntheses which provide cleaner processes and hence, greener chemistries. These processes quite often use transition metal catalysts that have several advantages of traditional reaction chemistries.
By J. Fisher and J. Hurry, The Dow Chemical Company
They allow for fast reactions which require fewer steps than stoichimetric reagents. They operate at lower temperatures, decreasing capital costs and providing a higher degree of safety. One example is the Ullman reaction, which uses copper to couple two aryl halides to form the biaryl.
Other examples of coupling chemistries which use transitional metal catalysts are the Heck, Suzuki and Fukuyama reactions. In the transitional metals, the platinum group metals (PGM) are commonly used for pharmaceutical syntheses. PGMs include ruthenium (Ru), rhodium (Rh), palladium (Pd), osmium (Os), iridium (Ir) and platinum (Pt). Figure 1 shows an example of a hydrogenation reaction catalyzed by palladium.
In a move toward sustainable processing, it is ideal to recover these expensive catalysts, while minimizing the yield loss of the API to the recovery method. The following article will discuss improved options for catalyst recoveries.
Catalyzed reactions can be broadly characterized into two categories: heterogeneous and homogeneous. In heterogeneous reactions, the phase of catalyst is different from that of reactants, i.e. solid, liquid or gas. However, it can also mean that the miscibility of the catalyst is different from the reaction mixture too. With homogeneous reactions, the catalyst and other reactants are the same phase and are miscible with one another. The type of reaction will have implications for the recovery of the catalyst post-reaction.
Solvent extraction, nanofiltration, chemical precipitation, and adsorption are catalyst recovery techniques typically employed in industrial and pharmaceutical processes. Nanofiltration recovery is used only with homogeneous processes and catalysts are immediately re-used in the liquid phase. Therefore, nanofiltration is not particularly amenable to incineration and recovery of the catalysts for later use. Solvent extraction and chemical precipitation tend to be somewhat non-specific and can lead to yield losses of the API.
Adsorptive recovery techniques can include materials such as activated carbon and ion exchange resins to recover either homogeneous catalysts, or homogeneous ligand and/or leachate. With a homogeneous catalyst, the carbon or resin will selectively absorb the catalyst. The catalyst is then stripped from the adsorbent for reuse or sent to a recovery specialist for incineration and recovery. For a homogeneous ligand and/or leachate, a fragment of a heterogeneous catalyst is shed and then dissolved in the phase where the chemical transformation is taking place. The catalyst is filtered from the batch and the ligand and and/or leachate that remains in solution is removed via resin or carbon treatment.
Whichever is the case, the spent heterogeneous catalyst (or carbon used to scrub the batch of catalyst leachates, ligands, and/or impurities) is washed with fresh solvent. These solvents can vary widely from process to process in pharmaceutical production, but typical organic solvents used in synthesis are MTBE, dichloromethane, tetrahydrofuran (THF), 2-methyl THF, acetonitrile, toluene, acetone, methanol, ethanol, ethyl acetate, or water.
The Problem with Carbon
Historically, adsorption techniques for catalyst recovery have involved activated carbon. Carbon is well characterized, it is relatively inexpensive and it is relatively effective in removing spent catalysts from process streams. However, carbon suffers from several drawbacks. First, it can be difficult to handle and filter from the process stream. This is usually overcome by operating the removal process with pre-packed carbon cartridges. The second, and more difficult, drawback is the non-specific adsorptive nature of carbon. Carbon will remove the catalyst, but it will also bind a percentage of the API. This leads to yield losses and increased production costs. The selective removal of the catalyst would be a more attractive adsorption option.
A More Selective Approach: Ion Exchange Resins
Ion exchange resin technology has been used for over 60 years in the biopharmaceutical industry, primarily for purification of APIs. Molecules as diverse as antibiotics, oligonucleotides and monoclonal antibodies have been purified using ion exchange resins. Specialized ion exchange resins are also used as scavengers for chemical synthesis, removing byproducts and un-reacted components. These uses range in scale from laboratory bench-top operations, such as solid phase extraction (SPE) strategies with combinatorial libraries, to full-scale production. One example of a scavenger resin at production-scale in industrial processing is the use of iminodiacetic functionalized resin for metal removal. The waste effluent before discharge still contains some low levels of heavy metals, about 5 to 20 ppm. A polishing unit containing the chelating resin installed in a packed-column merry-go-round configuration can bring the total concentration of metals below 0.1 ppm even in the presence of high concentrations of sodium or calcium salts.
Polymeric resin-based catalyst removal strategies have several advantages, including:
- A more selective removal of the catalyst, leading to higher recoveries of API
- Providing solid waste for incineration or selective desorption of the catalyst
There are a number of different polymeric resin chemistries that can be used in place of carbon. These resins selectively bind divalent metals, including platinum group metals. Some examples of these resins are listed below in Table 1, and the structure of an iminodiacetic acid resin is shown in Figure 2.